Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Eperisone→

Eperisone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
64840-90-0
Molecular formula
C17H25NO
Molecular weight
259.4 g/mol
Drug class
Centrally acting skeletal-muscle relaxantpiperidine derivative
Mechanism of action
Acts on spinal reflex pathways and reduces reflex-mediated skeletal-muscle tone. Experimental work supports depression of spinal reflex activity and effects on voltage-gated sodium/calcium channels; a 2024 study also reported P2X7 antagonism, but the established clinical mechanism remains incompletely elucidated.
Indications / reported uses
  • Improvement of myotonic conditions associated with neck-shoulder-arm syndrome, scapulohumeral periarthritis and low back pain
  • Spastic paralysis associated with selected cerebrovascular, spinal and other neurological disorders in the cited Japanese product information; authorisation varies by country

Sources: Singapore National Drug Formulary — Myonal (eperisone hydrochloride) · PubMed randomised trial in acute musculoskeletal spasm · PubMed mechanism study · Chemical and Pharmaceutical Bulletin (2024; P2X7 study) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Eperisone Environmental Risk Assessment (ERA) (the Eperisone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.